Poly(γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice

Vaccine

Volumn 27, Issue 42, 2009, Pages 5896-5905

  Okamoto, Shigefumi ^a   Matsuura, Masaaki ^a,b   Akagi, Takami ^b,c   Akashi, Mitsuru ^b,c   Tanimoto, Takeshi ^b   Ishikawa, Toyokazu ^b   Takahashi, Michiaki ^d   Yamanishi, Koichi ^a   Mori, Yasuko ^a,e  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Osaka University   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Influenza vaccine; Mucosal immunization; Poly glutamic acid nano particles ( PGA NPs)

Indexed keywords

GLUTAMIC ACID DERIVATIVE; INFLUENZA VACCINE; NANOPARTICLE; POLY(GAMMA GLUTAMIC ACID) NANOPARTICLE; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CYTOKINES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; POLYGLUTAMIC ACID; SPLEEN;

EID: 69749106545     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.037     Document Type: Article

References (31)

1. Wright P.F., Neuman G., and Kawaoka Y. Orthomyxoviruses. In: Knipe D.M., Howley P.M., Grifin D.E., Martin M.A., Ramb R.A., Roizman B., et al. (Eds). Fields virology. 5th ed. (2007), Lippincott-Raven, Philadelphia 1691-1740
2. McCullers J.A., and Rehg J.E. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. The Journal of Infectious Diseases 186 August (3) (2002) 341-350
3. Okamoto S., Kawabata S., Nakagawa I., Okuno Y., Goto T., Sano K., et al. Influenza A virus-infected hosts boost an invasive type of Streptococcus pyogenes infection in mice. Journal of Virology 77 April (7) (2003) 4104-4112
4. Okamoto S., Kawabata S., Terao Y., Fujitaka H., Okuno Y., and Hamada S. The Streptococcus pyogenes capsule is required for adhesion of bacteria to virus-infected alveolar epithelial cells and lethal bacterial-viral superinfection. Infection and Immunity 72 October (10) (2004) 6068-6075
5. Sweet C., and Smith H. Pathogenicity of influenza virus. Microbiological Reviews 44 June (2) (1980) 303-330
6. Nichol K.L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine 21 May (16) (2003) 1769-1775
7. Nichol K.L., Wuorenma J., and von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Archives of Internal Medicine 158 September (16) (1998) 1769-1776
8. Okamoto S., Kawabata S., Fujitaka H., Uehira T., Okuno Y., and Hamada S. Vaccination with formalin-inactivated influenza vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. Vaccine 22 July (21-22) (2004) 2887-2893
9. Belshe R.B. Current status of live attenuated influenza virus vaccine in the US. Virus Research 103 July (1-2) (2004) 177-185
10. Quan F.S., Compans R.W., Nguyen H.H., and Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. Journal of Virology 82 February (3) (2008) 1350-1359
11. Tamura S.I., Asanuma H., Ito Y., Hirabayashi Y., Suzuki Y., Nagamine T., et al. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. European Journal of Immunology 22 February (2) (1992) 477-481
12. Tumpey T.M., Renshaw M., Clements J.D., and Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. Journal of Virology 75 June (11) (2001) 5141-5150
13. Couch R.B., and Kasel J.A. Immunity to influenza in man. Annual Review of Microbiology 37 (1983) 529-549
14. Liew F.Y., Russell S.M., Appleyard G., Brand C.M., and Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. European Journal of Immunology 14 April (4) (1984) 350-356
15. Tamura S., Samegai Y., Kurata H., Nagamine T., Aizawa C., and Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6 October (5) (1988) 409-413
16. Tamura S.I., Samegai Y., Kurata H., Kikuta K., Nagamine T., Aizawa C., et al. Enhancement of protective antibody responses by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine 7 June (3) (1989) 257-262
17. Mizuno D., Ide-Kurihara M., Ichinomiya T., Kubo I., and Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. Journal of Immunology 176 January (2) (2006) 1122-1130
18. Hirabayashi Y., Kurata H., Funato H., Nagamine T., Aizawa C., Tamura S., et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8 June (3) (1990) 243-248
19. Holmgren J., Svennerholm A.M., Gothefors L., Jertborn M., and Stoll B. Enterotoxigenic Escherichia coli diarrhea in an endemic area prepares the intestine for an anamnestic immunoglobulin A antitoxin response to oral cholera B subunit vaccination. Infection and Immunity 56 January (1) (1988) 230-233
20. Ichinohe T., Watanabe I., Ito S., Fujii H., Moriyama M., Tamura S., et al. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. Journal of Virology 79 March (5) (2005) 2910-2919
21. Okamoto S., Yoshii H., Akagi T., Akashi M., Ishikawa T., Okuno Y., et al. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25 November (49) (2007) 8270-8278
22. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. Journal of Immunology 178 March (5) (2007) 2979-2986
23. Akagi T., Higashi M., Kaneko T., Kida T., and Akashi M. In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(gamma-glutamic acid). Macromolecular Bioscience 5 July (7) (2005) 598-602
24. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. Journal of Immunology 156 May (10) (1996) 3892-3900
25. Akagi T., Kaneko T., Kida T., and Akashi M. Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier. Journal of Controlled Release 108 November (2-3) (2005) 226-236
26. Fromantin C., Jamot B., Cohen J., Piroth L., Pothier P., and Kohli E. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response. Journal of Virology 75 November (22) (2001) 11010-11016
27. Kang S.M., Yao Q., Guo L., and Compans R.W. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. Journal of Virology 77 September (18) (2003) 9823-9830
28. Tamura S., Asanuma H., Tomita T., Komase K., Kawahara K., Danbara H., et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12 September (12) (1994) 1083-1089
29. Verweij W.R., de Haan L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16 December (20) (1998) 2069-2076
30. Tamura S., Funato H., Hirabayashi Y., Kikuta K., Suzuki Y., Nagamine T., et al. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine 8 October (5) (1990) 479-485
31. Andreakos E., Williams R.O., Wales J., Foxwell B.M., and Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proceedings of the National Academy of Sciences of the United States of America 103 September (39) (2006) 14459-14464